Valens Company Signs Agreements With Mexican Drug Supplier To Provide CBD Oil And Prebiotic Products

The Valens Company Inc. VLNS VLNS confirmed Tuesday it had entered into two agreements with PMI Mexico, a subsidiary of Merger Group, one of the main drug suppliers of the Mexican government.

"The relationship we have built with PMI Mexico marks an important milestone for Valens' international expansion and the beginning of our Central and Latin America strategy," Tyler Robson, CEO, chair & co-founder of The Valens Company stated. "Predilife has significant and unique versatility in terms of reach and market potential given it can be consumed infused or uninfused with CBD. This enables unimpeded distribution of the product regardless of local cannabis regulations, providing Valens access to several international markets. This agreement diversifies our global strategy and increases our revenue streams through creative, non-traditional strategies that separate us from our peers."

Predilife is an agave-based prebiotic powder that has been submitted as a drug master file" (DMF) to the FDA.

Agreements Highlights

• Under the first agreement, Valens will supply CBD for PMI's ongoing pharmacokinetic (PK) stage medical trials, which are focused on anti-inflammatory applications of medical-grade, nano-water emulsified CBD oil. The clinical trial, which has already been approved by The Medical Ethics Board of Mexico, is set to begin once Valens' shipments arrive in Q1 of 2022. They will be conducted across private hospitals in Mexico. At the conclusion of the trial, Valens will be the sole manufacturer and global distributor in collaboration with PMI.
• Under the second agreement, Valens will manufacture and distribute CBD-infused and uninfused Predilife products globally while PMI will be responsible for the distribution of the Predilife products in Mexico.
• Valens will manufacture the products at its Green Roads facility in Florida, where they will be infused with CBD as required and then packaged and distributed through Valens' third-party supplier channels across Asia, U.S., Latin America and Mexico. The formulation will be offered in both powder and liquid sachets, initially for human consumption, with animal variations planned for the second half of 2022.

"In Valens we found a technological partner that was capable of providing us not only the required quality but also the technical support and necessary documents needed to comply with pharmaceutical regulations,” Gustavo Bustillo Ph.D., scientific director of PMI stated. “We look forward to initiating our commercial relationship and watching it expand globally over the coming years."

More recent news from The Valens:

The Valens Company Borrows $31.3M To Retire Its Debt And Strengthen Balance Sheet

Cannabis Producer The Valens Company Starts Trading On Nasdaq Dec 9

Price Action

The Valens shares closed Monday market session 4.99% lower at $2.52 per share.

Photo: Courtesy of CBD Infos on Unsplash